Unstable angina non ST elevation myocardial infarction anticoagulant therapy: Difference between revisions
Jump to navigation
Jump to search
m (Protected "Unstable angina / non ST elevation myocardial infarction anticoagulant therapy" [edit=sysop:move=sysop]) |
No edit summary |
||
Line 15: | Line 15: | ||
::b. For patients in whom a conservative strategy is selected, regimens using either [[enoxaparin]] or [[UFH]] (Level of Evidence: A) or [[fondaparinux]] (Level of Evidence: B) have established efficacy. | ::b. For patients in whom a conservative strategy is selected, regimens using either [[enoxaparin]] or [[UFH]] (Level of Evidence: A) or [[fondaparinux]] (Level of Evidence: B) have established efficacy. | ||
::c. In patients in whom a conservative strategy is selected and who have an increased risk of bleeding, [[fondaparinux]] is preferable. (Level of Evidence: B) | ::c. In patients in whom a conservative strategy is selected and who have an increased risk of bleeding, [[fondaparinux]] is preferable. (Level of Evidence: B) | ||
===Class IIa=== | ===Class IIa=== | ||
# For [[UA]] / [[NSTEMI]] patients in whom an initial conservative strategy is selected, [[enoxaparin]] or [[fondaparinux]] is preferable to [[UFH]] as [[anticoagulant therapy]], unless [[CABG]] is planned within 24 h. (Level of Evidence: B)}} | # For [[UA]] / [[NSTEMI]] patients in whom an initial conservative strategy is selected, [[enoxaparin]] or [[fondaparinux]] is preferable to [[UFH]] as [[anticoagulant therapy]], unless [[CABG]] is planned within 24 h. (Level of Evidence: B)}} | ||
==See Also== | |||
* [[The Living Guidelines: UA/NSTEMI | The UA / NSTEMI Living Guidelines: Vote on current recommendations and suggest revisions to the guidelines]] | |||
==Sources== | ==Sources== |
Revision as of 19:45, 1 June 2009
Cardiology Network |
Discuss Unstable angina non ST elevation myocardial infarction anticoagulant therapy further in the WikiDoc Cardiology Network |
Adult Congenital |
---|
Biomarkers |
Cardiac Rehabilitation |
Congestive Heart Failure |
CT Angiography |
Echocardiography |
Electrophysiology |
Cardiology General |
Genetics |
Health Economics |
Hypertension |
Interventional Cardiology |
MRI |
Nuclear Cardiology |
Peripheral Arterial Disease |
Prevention |
Public Policy |
Pulmonary Embolism |
Stable Angina |
Valvular Heart Disease |
Vascular Medicine |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Please Join in Editing This Page and Apply to be an Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Overview of Anticoagulant Therapy in UA / NSTEMI
ACC / AHA Guidelines (DO NOT EDIT) [1]
“ |
Class I
Class IIa
|
” |
See Also
Sources
- The ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction [1]
References
- ↑ 1.0 1.1 Anderson JL, Adams CD, Antman EM; et al. (2007). "ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine". JACC. 50 (7): e1–e157. PMID 17692738. Text "doi:10.1016/j.jacc.2007.02.013 " ignored (help); Unknown parameter
|month=
ignored (help)